Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound

Information

  • Patent Grant
  • 7311701
  • Patent Number
    7,311,701
  • Date Filed
    Friday, January 23, 2004
    20 years ago
  • Date Issued
    Tuesday, December 25, 2007
    16 years ago
Abstract
Methods and apparatus are provided for non-invasively treating patent foramen ovale using an ultrasound imaging system and a high intensity focused ultrasound system to selectively target high intensity ultrasound energy on either or both of a patient's septum primum or septum secundum.
Description
FIELD OF THE INVENTION

The present invention relates to methods and apparatus for treatment of patent foramen ovale, and more particularly, to the use of high intensity focused ultrasound non-invasively to treat patent foramen ovale.


BACKGROUND OF THE INVENTION

Up until the 1980s, there was dramatic growth in the creation of new surgical methods for treating a wide variety of previously untreated conditions. Over the past twenty years there has been a clear trend towards the invention of devices and methods that enable less-invasive treatment of such diseases, moving from invasive surgery, and then to less-invasive surgery, and to interventional techniques. Ultimately, it is desirable to move to totally non-invasive therapies.


Patent foramen ovale (PFO) is characterized by a persistent fetal opening between the left and right atria of the heart that allows blood to bypass the lungs. In most people, this opening permanently closes during the first few months after birth. However, a PFO is present in up to 15 percent of adults.


PFO may be associated with various heart conditions including paradoxical embolus, in which an embolus arising in venous circulation gains access to the arterial circulation through the PFO, thereby resulting in stroke or transient ischemic attack. Closure of PFO using a transcatheter approach may be medically necessary for patients with a history of cryptogenic stroke that are not candidates for anticoagulant therapy. Implantable devices, such as those of AGA Medical Corporation (Golden Valley, Minn.) and NMT Medical, Inc. (Boston, Mass.) are used to close PFOS.


It would be desirable to develop methods of treating PFO that are even less invasive than transvascular interventional techniques, thereby eliminating the need for catheters.


The following devices pertain to the use of high intensity focused ultrasound (HIFU) energy to weld the tissues of a PFO closed. Each device is used for application of energy to the tissues to be sealed. Heating of the tissues of the PFO by the HIFU causes a healing response which causes the formerly separate tissues of the PFO to heal together. In some embodiments, the energy denatures the collagen of the tissues of the different portions of the PFO, and the tissues are caused to remain in close apposition in order to allow the collagen to bond while the tissue return to normal body temperature.


By way of example, WO 99/18871 and 99/18870 to Laufer, et al. (now abandoned) describe the heating of the tissue of a PFO to induce closure through natural wound healing. These, however are invasive devices which require entering and crossing the PFO. Additionally, U.S. Pat. No. 6,562,037 to Paton et al. describes in detail methods and considerations for the rejoining of two tissue sections through the precise application of energy in a two-stage algorithm, wherein all voltage levels used are empirically derived and pre-programmed into the energy delivery control system. Again, however, all devices described would need to be in contact with the tissues to be joined. Relevant articles from the clinical literature include “High-burst-strength, feedback-controlled bipolar vessel sealing”, Kennedy et al., Surg Endosc (1998) 12:876-878. This article describes the development of a system for use in open or laparoscopic surgical procedures for achieving hemostasis in large-diameter arteries through the use of RF welding.


A wide variety of energy modes have been used to create lesions using epicardial or intracardiac probes. Radio-frequency electrical energy, microwaves, cryothermia probes, alcohol injection, laser light, and ultrasound energy are just a few of the technologies that have been pursued.


Separately, several groups have developed focused ultrasound devices with both imaging and therapeutic capabilities. These efforts began perhaps with lithotripsy, in which a high power focused ultrasound system developed by Dornier Medizintechnik, Germany, was used to break up kidney stones in the body. The kidney stones generally are located within the body at a significant depth from the skin. One ultrasound imaging system is used to aim the system at the kidney stones, and then a second, high energy ultrasound system delivers energy that breaks up the stones so they can be passed.


More recently, Therus Corp of Seattle, Wash., has developed a system to seal blood vessels after the vessels have been punctured to insert sheaths and catheters. The Therus system shrinks and seals femoral artery punctures at a depth of approximately 5 cm.


In addition, Timi-3 Systems, Inc., Santa Clara, Calif., has developed and is testing a trans-thoracic ultrasound energy delivery system to accelerate the thrombolysis process for patients suffering an acute myocardial infarction. This system delivers energy at a frequency intended to accelerate thrombolysis without damaging the myocardium or vasculature of the heart.


Epicor Medical, Inc. of Sunnyvale, Calif., has developed a localized high intensity focused ultrasound (“HIFU”) device to create lesions in the atrial walls. The Epicor device is a hand-held intraoperative surgical device, and is configured to be held directly against the epicardium or outside wall of the heart. When energized, the device creates full-thickness lesions through the atrial wall of the heart, and has demonstrated that ultrasound energy may be safely and effectively used to create atrial lesions, despite presence of blood flow past the interior wall of the atrium.


In addition, Transurgical, Inc., Setauket, N.Y. has been actively developing HIFU devices. However, while the Epicor Medical devices are placed in close approximation against the outside of the heart, the Transurgical devices are directed to intravascular catheters for heating or ablating tissue in the heart and require that the catheter be brought into close approximation with the targeted tissue.


In view of the aforementioned limitations or previously-known devices and methods, it would be desirable to provide methods and apparatus for treating PFO by heating or ablating tissue at a distance from that tissue, so that the procedure may be performed non-invasively.


It also would be desirable to provide methods and apparatus for treating PFO by applying energy from outside the body or from organs, such as the esophagus, that are easily accessible via natural body openings.


SUMMARY OF THE INVENTION

In view of the foregoing, it is an object of the present invention to provide methods and apparatus for treating PFO so as to cause closure by ablating or applying energy to weld the tissue at a distance from that tissue, so that the procedure may be performed non-invasively.


It is another object of the present invention to provide methods and apparatus for treating PFO by applying energy from outside the body or from neighboring organs, such as the esophagus, that are easily accessible.


These and other objects of the present invention are accomplished by providing methods and apparatus that enable a physician to image tissue within the body that is to be heated or ablated, and then to heat or ablate that tissue using a completely or relatively non-invasive procedure, and with little or no anesthesia. Advantageously, the methods and apparatus of the present invention are expected to be cost-effective and time-efficient to perform compared to the previously-known surgical and interventional procedures.





BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects and advantages of the present invention will be apparent upon consideration of the following detailed description, taken in conjunction with the accompanying drawings, in which like reference characters refer to like parts throughout, and in which:



FIG. 1 is a schematic view of an illustrative imaging and treatment ultrasound system of the present invention;



FIG. 2 is a schematic view of an illustrative display of the imaging and treatment ultrasound system of the present invention;



FIG. 3 is a schematic view showing the imaging and treatment ultrasound system of FIG. 1 disposed adjacent to a cross-section of a patient's thorax; and



FIG. 4 is a schematic view of the distal region of a catheter-based high intensity focused ultrasound array.





DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to methods and apparatus for creating lesions in the walls of the heart or for ablating or welding the tissue of a PFO in a non-invasive manner using high intensity focused ultrasound (HIFU). Previously-known HIFU systems, such as those being developed by Epicor Medical or Transurgical, require close approximation of the HIFU device to the target tissue. These systems are not adapted for PFO closure. The methods and apparatus of the present invention overcome this drawback by providing systems that enable the creation of lesions in the heart wall from a greater distance.


Referring to FIG. 1, apparatus constructed in accordance with the principles of the present invention is described. System 10 comprises head 11 housing ultrasound imaging system 12 and high intensity focused ultrasound energy (“HIFU”) system 14. Ultrasound imaging system 12 and HIFU system 14 may have in common all or just a subset of the transducers and related components, operating in different modes to image or ablate. Head 11 is mounted on arm 13 that permits the head to be positioned in contact with a patient (not shown) lying on table 15. Head 11 also may be a handheld unit, not needing an arm 13 to support or position it. System 10 includes controller 16 that controls operation of imaging system 12 and HIFU system 14. Monitor 18 displays images output by imaging system 12 that allows the clinician to identify the desired locations on the walls of the heart to be treated.


In accordance with the methods of the present invention, controller 16 and monitor 18 also are programmed to indicate the focus of the HIFU energy relative to the image of the tissue cross-section. FIG. 2 shows illustrative screen display 19 of monitor 18 wherein the outline T of the tissue, as imaged by imaging system 12, and a marker corresponding to the location of focal point F of HIFU system 14, may be seen.


When activated, the HIFU system delivers ablative energy to the specific location shown on monitor 18 (focal point F in FIG. 2), thus enabling safe creation of lesions or tissue welds. Because the HIFU system is configured to deliver energy from a number of sources focused towards the target tissue area, intervening tissue is subjected to only a fraction of the energy deposited in the target tissue receives, and thus the intervening tissue is not significantly heated or ablated.


Referring still to FIG. 1, ultrasound imaging system 12 may be similar in design to previously-known trans-thoracic ultrasound imaging systems, and are per se known. High intensity focused ultrasound system 14 may comprise one or more HIFU generators 20 constructed as described in U.S. Patent Publication No. U.S. 20010031922A1. As mentioned before, imaging system 12 and HIFU system 14 also may use common elements. Preferably, each HIFU generator 20 is the same as or is disposed approximately in the same plane as the imaging elements of ultrasound imaging system 12, so that the focus of HIFU system 14 occurs in the plane of the target tissue imaged by ultrasound imaging system 12. In addition, this arrangement advantageously ensures that the HIFU energy will reach the target.


In a preferred embodiment, HIFU generators 20 deliver energy at a frequency optimized for heating myocardium, so that the lesions created will weld, occlude, or lead to the occlusion of the patent foramen ovale. Once the lesions are created, a gradual healing process is begun in which the lesions fibrose, thus permanently sealing the opening.


While it may be possible to image and heat simultaneously, it may occur that the output of HIFU system 14 may interfere with the ability to image the tissue using ultrasound imaging system 12. Accordingly, controller 16 may be programmed to time-gate operation of imaging system 12 and HIFU system 14, so that the tissue is alternately imaged and ablated at a frequency of up to several times per second.


In order to apply energy to the wall of the septa of the heart sufficient to occlude the PFO, it may be desirable to slowly move the focus of the HIFU system along the wall of the septa during the ablation process. While this may be accomplished by manually moving the HIFU system, it may alternatively be desirable to automate the process. For example, controller 16 may include suitable programming and joystick 22, or other input device, for refocusing the focal point of HIFU system 14 along a desired trajectory.


Referring now to FIG. 3, according to an aspect of the present invention, an exemplary method of using the HIFU system to treat PFO is described. More particularly, the HIFU system is used to create localized tissue heating of the septum primum and septum secundum that will lead to occlusion of a PFO. The consequent healing process is expected to cause the septum primum and septum secundum to heal together, thereby permanently closing the PFO or resulting in acute welding of the tissues. Even if this non-invasive treatment were to be effective in closing PFO in only a small percentage of cases, the procedure would likely become the first choice for use in initial therapy.


The tissues of the septum primum and the septum secundum preferably are in contact when the energy is applied to facilitate welding of the PFO. In cases where heat is applied to cause closure through scar formation and subsequent healing, it is also desirable to have the tissue in apposition to ensure that the correct target tissues are heated to an adequate degree to cause tissue damage. Adequate apposition exists in many patients in the absence of an elevated right atrial pressure. However, in some cases it may be necessary or desirable to artificially increase the pressure gradient between the right and left atria to ensure closure of the PFO and/or to increase the contact pressure between the septum primum and septum secundum.


Closure of the PFO or increased contact pressure between the septum primum and septum secundum can be achieved noninvasively through a variety of known techniques using medications, mechanical expedients, or a combination of the two. By way of example, briefly applying external pressure to a patient's jugular veins will temporarily limit blood flow into the superior vena cava and hence the right atrium. Of course, this lowers the right atrial pressure relative to the left atrial pressure, thereby creating the desired closure or increase in contact pressure. Alternatively, the desired closure or increase in contact pressure may be achieved by administering drugs that increase the patient's blood pressure by increasing heart rate and/or peripheral resistance. One suitable drug for increasing heart rate is epinephrine. As a further alternative, such drugs may be administered in combination with the application of pressure to the patient's jugular veins.


In the system shown in FIG. 3 the focus of the HIFU system is fixed at a certain point within the field of the ultrasound image. For example, the ultrasound image might show a picture of rectangular planar cross-section of tissue with a fixed focus of the HIFU energy in the center of the field. In operation, the clinician manually moves the probe until the desired tissue is in the target area, and then fires the HIFU system to ablate the tissue and occlude or weld the PFO. In order to ablate tissue located less than 130 mm below the skin and still retain a continuous fluid path from the probe to the target, the HIFU system includes fluid-filled balloon 24 that covers the face of the probe.


Balloon 24 preferably is filled with water and enables the clinician to reposition the probe at a variable distance from the skin. Balloon 24 also permits the clinician to position the probe at any desired angle to target tissue not aligned directly under the focal point of HIFU system 14. Alternatively, the patient could sit in a tub of water, so the patient's chest and the probe were both underwater, again ensuring a continuous fluid path.


As a further alternative, controller 16 may be programmed so that the depth of the focal point of the HIFU system is depth-adjustable relative to the imaged tissue. Advantageously, the depth of the targeted tissue then could be adjusted relative to the imaged field, so a smaller fluid-filled balloon, or no balloon, is used to maintain fluid contact while adjusting the angle of the imaged section or make minor changes in the depth of the targeted tissue. WIPO Patent Publication No. WO/0145550A2 to Therus describes several ways to adjust the depth of the focused energy by changing the radius of curvature of one or more of the ultrasound generators. Alternatively, the direction of several focused energy generators of relatively fixed focal length could be shifted relative to one another to move the focal point.


In accordance with the principles of the present invention, focused energy is applied from outside the patient's body. Because ultrasound energy does not travel coherently through non-fluid filled tissue, such as the lungs, positioning of the ultrasound imaging system and HIFU system at certain angles may be more advantageous for treatment of specific areas of the heart.


Accordingly, it may be desirable to locate the imaging system and HIFU system on a movable arm or to position it by hand so as to permit other external approaches, such as from below the diaphragm on the left anterior side of the body, so the ultrasound has a coherent path through the diaphragm and apex and ventricles of the heart to the septa. Application of the probe also may be made along a patient's back.


While in the preferred embodiment described hereinabove energy is delivered from outside the body, situations may arise where it is difficult to deliver the energy to the PFO tissue. Referring now to FIG. 4, and in accordance with another aspect of the present invention, methods and apparatus are provided for positioning a probe inside the body and closer to the targeted tissue, but still not necessarily adjacent to it. Intraluminal probe 30 is configured to deliver HIFU energy to the heart from the esophagus, from the aorta, or from the great veins of the heart such as the inferior vena cava, superior vena cava, or the right atrium itself.


This approach is fundamentally different from previously-known methods of performing ablation during surgical procedures using epicardial probes or during interventional procedures using intracardiac ablation catheters. These previously-known devices are designed to be in direct contact or at least very close proximity (e.g., within 5 mm) of the target tissue, and are not designed to avoid ablation of intervening tissue between the probe and the target tissue.


Still referring to FIG. 4, catheter 30 preferably has a diameter in a range of 5 to 10 mm for vascular devices, and a diameter in a range of 5 to 20 mm for an esophageal device. Imaging elements 32 and HIFU elements 34 are arranged linearly along the longitudinal axis of the catheter.


The linear nature of the imaging element and HIFU element array may impose limitations on the ability to reposition the device. While translation and rotation of the catheter may be relatively easy, it is contemplated that it may be difficult to move the device very far to one side or another within a relatively small-diameter body lumen.


Accordingly, intraluminal catheter 30 preferably is configured to adjust the focal point of the HIFU system with respect to both longitudinal position and depth. This may be accomplished by programming the controller used with intraluminal catheter 30 to adjust the focal point of the HIFU system, as described above. Alternatively, refocusing of the array of HIFU elements may be achieved by locating individual HIFU elements on independently steerable actuators 36. Actuators 36 are controlled by the system controller and permit the clinician to move the focal point of the HIFU array to any desired point in the field of view of the imaging system.


In accordance with another aspect of the present invention, methods of using intraluminal catheter 30 to heat or ablate septal tissues from the esophagus to treat PFO are described. The esophagus is separated from the PFO by only about 20-25 mm, such that a lesion may be easily made in the PFO using a probe capable of delivering energy at a distance of approximately 20-50 mm.


As described above, intraluminal catheter 30 preferably is configured, either mechanically or by suitable software algorithms, to move its focal point to enable a continuous linear ablation or heat affected zone without moving the device. Alternatively, the HIFU array of the catheter may be configured to create a linear ablation or heat affected zone, or have a fixed-focus so that a linear ablation or heat affected zone may be created by translating the HIFU array within the esophagus.


In addition, it may be beneficial to cool tissue surrounding the HIFU array of intraluminal catheter 30, to further reduce the risk of damage to the esophagus. Intraluminal catheter 30 may therefore include a water jacket that circulates fluid around the HIFU array to prevent any heat generated by the array or ultrasound energy absorbed by the esophagus from causing any tissue damage.


Although preferred illustrative embodiments of the present invention are described above, it will be evident to one skilled in the art that various changes and modifications may be made without departing from the invention. It is intended in the appended claims to cover all such changes and modifications that fall within the true spirit and scope of the invention.

Claims
  • 1. A method of treating patent foramen ovale comprising: providing a catheter having a distal portion housing an ultrasound imaging system and a high intensity focused ultrasound system disposed in alignment with the ultrasound imaging system;disposing the distal portion of the catheter within a patient's body lumen;operating the ultrasound imaging system to generate an image of a portion of cardiac tissue; andoperating the high intensity focused ultrasound system, guided by the image, to heat or ablate either or both of the patient's septum primum or septum secundum.
  • 2. The method of claim 1, wherein the body lumen is the aorta.
  • 3. The method of claim 1, wherein the body lumen is the right atrium.
  • 4. The method of claim 1, wherein the body lumen is the inferior vena cava.
  • 5. The method of claim 1, wherein the body lumen is the superior vena cava.
  • 6. The method of claim 1 further comprising generating and displaying a marker corresponding to a focal point of the high intensity focused ultrasound system on the image.
  • 7. The method of claim 1 further comprising modifying a location of the treatment by adjusting a location of a focal point of the high intensity focused ultrasound system.
  • 8. The method of claim 7 wherein the location of the focal point of the high intensity focused ultrasound system is adjusted within a two-dimensional plane orthogonal to an axis of the high intensity focused ultrasound system.
  • 9. The method of claim 7 wherein the location of the focal point of the high intensity focused ultrasound system is adjusted by modifying a location of a depth of the focal point of the high intensity focused ultrasound system.
  • 10. The method of claim 1 further comprising apposing the patient's septum primum and septum secundum noninvasively using drugs, noninvasive procedures, or a combination thereof.
  • 11. The method of claim 1 further comprising increasing contact pressure between the patient's septum primum and septum secundum is noninvasively using drugs, noninvasive procedures, or a combination thereof.
REFERENCE TO RELATED APPLICATIONS

This application claims priority from and is a Continuation-In-Part of U.S. provisional patent application Ser. No. 60/477,532, filed Jun. 10, 2003.

US Referenced Citations (225)
Number Name Date Kind
2275167 Bierman Mar 1942 A
2580628 Welsh Jan 1952 A
2888928 Seiger Jun 1959 A
3490442 Streu Jan 1970 A
3862627 Hans, Sr. Jan 1975 A
3874388 King et al. Apr 1975 A
3906955 Roberts Sep 1975 A
4307720 Weber, Jr. Dec 1981 A
4326529 Doss et al. Apr 1982 A
4473077 Noiles et al. Sep 1984 A
4485817 Swiggett Dec 1984 A
4556065 Hoffmann Dec 1985 A
4562838 Walker Jan 1986 A
4682596 Bales et al. Jul 1987 A
4788975 Shturman et al. Dec 1988 A
4798594 Hillstead Jan 1989 A
4832048 Cohen May 1989 A
4884567 Elliott et al. Dec 1989 A
4895565 Hillstead Jan 1990 A
4911159 Johnson et al. Mar 1990 A
4919129 Weber, Jr. et al. Apr 1990 A
4929246 Sinofsky May 1990 A
4976711 Parins et al. Dec 1990 A
4986889 Charamathieu et al. Jan 1991 A
5041095 Littrell Aug 1991 A
5042707 Taheri Aug 1991 A
5055100 Olsen Oct 1991 A
5056517 Fenici Oct 1991 A
5057107 Parins et al. Oct 1991 A
5071417 Sinofsky Dec 1991 A
5071418 Rosenbaum Dec 1991 A
5078717 Parins et al. Jan 1992 A
5099827 Melzer et al. Mar 1992 A
5125928 Parins et al. Jun 1992 A
5156608 Troidl et al. Oct 1992 A
5156613 Sawyer Oct 1992 A
5171311 Rydell Dec 1992 A
5195959 Smith Mar 1993 A
5196007 Ellman et al. Mar 1993 A
5197963 Parins Mar 1993 A
5207670 Sinofsky May 1993 A
5209756 Seedhom et al. May 1993 A
5290278 Anderson Mar 1994 A
5292362 Bass et al. Mar 1994 A
5295955 Rosen et al. Mar 1994 A
5300065 Anderson Apr 1994 A
5336221 Anderson Aug 1994 A
5336252 Cohen Aug 1994 A
5342413 Hirschberg et al. Aug 1994 A
5345935 Hirsch Sep 1994 A
5370675 Edwards et al. Dec 1994 A
5380304 Parker Jan 1995 A
5383917 Desai et al. Jan 1995 A
5405322 Lennox et al. Apr 1995 A
5409479 Dew et al. Apr 1995 A
5409481 Poppas et al. Apr 1995 A
5500012 Brucker et al. Mar 1996 A
5505730 Edwards Apr 1996 A
5507744 Tay et al. Apr 1996 A
5540677 Sinofsky Jul 1996 A
5569239 Sinofsky Oct 1996 A
5571216 Anderson Nov 1996 A
5575772 Lennox Nov 1996 A
5584872 Lafontaine et al. Dec 1996 A
5611794 Sauer et al. Mar 1997 A
5620481 Desai et al. Apr 1997 A
5626607 Malecki et al. May 1997 A
5662643 Kung et al. Sep 1997 A
5665109 Yoon Sep 1997 A
5669934 Sawyer Sep 1997 A
5693078 Desai et al. Dec 1997 A
5709224 Behl Jan 1998 A
5713891 Poppas Feb 1998 A
5725522 Sinofsky Mar 1998 A
5730742 Wojciechowicz Mar 1998 A
5749895 Sawyer et al. May 1998 A
5782899 Imran Jul 1998 A
5814065 Diaz Sep 1998 A
5824015 Sawyer Oct 1998 A
5827265 Glinsky et al. Oct 1998 A
5846196 Siekmeyer et al. Dec 1998 A
5855312 Toledano Jan 1999 A
5871443 Edwards et al. Feb 1999 A
5919200 Stambaugh et al. Jul 1999 A
5925078 Anderson Jul 1999 A
5928266 Kontos Jul 1999 A
5931165 Reich et al. Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5972023 Tanner et al. Oct 1999 A
5972024 Northrup, III et al. Oct 1999 A
6004316 Laufer Dec 1999 A
6036699 Andreas et al. Mar 2000 A
6056760 Koike et al. May 2000 A
6063081 Mulier May 2000 A
6063085 Tay May 2000 A
6083223 Baker Jul 2000 A
6086570 Aboul-Hosn et al. Jul 2000 A
6086586 Hooven Jul 2000 A
6087552 Gregory Jul 2000 A
6132429 Baker Oct 2000 A
6149660 Laufer et al. Nov 2000 A
6156032 Lennox Dec 2000 A
6168594 Lafontaine Jan 2001 B1
6211335 Owen et al. Apr 2001 B1
6221068 Fried et al. Apr 2001 B1
6236875 Bucholz et al. May 2001 B1
6257241 Wampler Jul 2001 B1
6290674 Roue et al. Sep 2001 B1
6302898 Edwards et al. Oct 2001 B1
6323037 Lauto et al. Nov 2001 B1
6325798 Edwards et al. Dec 2001 B1
6355030 Aldrich et al. Mar 2002 B1
6375668 Gifford et al. Apr 2002 B1
6383198 Hamilton May 2002 B1
6391048 Ginn et al. May 2002 B1
6391049 McNally et al. May 2002 B1
6398779 Buysee et al. Jun 2002 B1
6398782 Pecor et al. Jun 2002 B1
6398797 Bombard et al. Jun 2002 B2
6401720 Stevens et al. Jun 2002 B1
6409720 Hissong et al. Jun 2002 B1
6413254 Hissong et al. Jul 2002 B1
6419669 Frazier et al. Jul 2002 B1
6423057 He et al. Jul 2002 B1
6436088 Frazier et al. Aug 2002 B2
6451013 Bays et al. Sep 2002 B1
6456865 Samson Sep 2002 B2
6458100 Roue et al. Oct 2002 B2
6475213 Whayne et al. Nov 2002 B1
6482224 Michler et al. Nov 2002 B1
6514250 Jahns et al. Feb 2003 B1
6558314 Adelman et al. May 2003 B1
6558382 Jahns et al. May 2003 B2
6562037 Paton et al. May 2003 B2
6583117 Owen et al. Jun 2003 B2
6584360 Francischelli et al. Jun 2003 B2
6589237 Woloszko Jul 2003 B2
6606523 Jenkins Aug 2003 B1
6641604 Adelman Nov 2003 B1
6645202 Pless et al. Nov 2003 B1
6645225 Atkinson Nov 2003 B1
6648897 Hamilton Nov 2003 B2
6652518 Wellman Nov 2003 B2
6669693 Friedman Dec 2003 B2
6676685 Pedros et al. Jan 2004 B2
6682546 Amplatz Jan 2004 B2
6692450 Coleman Feb 2004 B1
6702835 Ginn Mar 2004 B2
6712804 Roue et al. Mar 2004 B2
6712836 Berg et al. Mar 2004 B1
6716211 Mulier et al. Apr 2004 B2
6726718 Carlyle et al. Apr 2004 B1
6730108 Van Tassel et al. May 2004 B2
6733498 Paton et al. May 2004 B2
6736810 Hoey et al. May 2004 B2
6755790 Stewart et al. Jun 2004 B2
6770072 Truckai et al. Aug 2004 B1
6776784 Ginn Aug 2004 B2
6790218 Jayaraman Sep 2004 B2
6846319 Ginn et al. Jan 2005 B2
6887238 Jahns May 2005 B2
6893431 Naimark et al. May 2005 B2
6926716 Baker et al. Aug 2005 B2
6929644 Truckai et al. Aug 2005 B2
6932812 Crowley et al. Aug 2005 B2
6946134 Rosen et al. Sep 2005 B1
7025756 Frazier et al. Apr 2006 B2
7165552 Deem et al. Jan 2007 B2
20010037129 Thill Nov 2001 A1
20010051803 Desai et al. Dec 2001 A1
20020128672 Dinger et al. Sep 2002 A1
20020143322 Haghighi Oct 2002 A1
20030028189 Woloszko et al. Feb 2003 A1
20030045893 Ginn Mar 2003 A1
20030045901 Opolski Mar 2003 A1
20030050665 Ginn Mar 2003 A1
20030065364 Wellman et al. Apr 2003 A1
20030069570 Witzel Apr 2003 A1
20030078578 Truckai et al. Apr 2003 A1
20030092988 Makin May 2003 A1
20030093071 Hauck et al. May 2003 A1
20030120268 Bertolero et al. Jun 2003 A1
20030144652 Baker et al. Jul 2003 A1
20030144694 Chanduszko et al. Jul 2003 A1
20030158551 Paton et al. Aug 2003 A1
20030199868 Desai et al. Oct 2003 A1
20030208232 Blaeser Nov 2003 A1
20030225421 Peavey et al. Dec 2003 A1
20030233091 Whayne et al. Dec 2003 A1
20040059347 Hamilton Mar 2004 A1
20040092973 Chanduszko et al. May 2004 A1
20040098031 Van der Burg et al. May 2004 A1
20040098042 Devellian et al. May 2004 A1
20040102721 McKinley May 2004 A1
20040143292 Marino et al. Jul 2004 A1
20040153057 Davison Aug 2004 A1
20040153098 Chin et al. Aug 2004 A1
20040176799 Chanduszko et al. Sep 2004 A1
20040220596 Frazier et al. Nov 2004 A1
20040243122 Auth Dec 2004 A1
20040249398 Ginn Dec 2004 A1
20050021059 Cole et al. Jan 2005 A1
20050033288 Auth et al. Feb 2005 A1
20050033327 Gainor et al. Feb 2005 A1
20050055050 Alfaro Mar 2005 A1
20050065506 Phan Mar 2005 A1
20050065509 Coldwell et al. Mar 2005 A1
20050070923 McIntosh Mar 2005 A1
20050075665 Brenzel et al. Apr 2005 A1
20050119675 Adams et al. Jun 2005 A1
20050125032 Whisenant et al. Jun 2005 A1
20050171526 Rioux et al. Aug 2005 A1
20050187568 Klenk et al. Aug 2005 A1
20050192626 Widomski et al. Sep 2005 A1
20050192627 Whisenant et al. Sep 2005 A1
20050192654 Chanduszko et al. Sep 2005 A1
20050209636 Widomski et al. Sep 2005 A1
20050216054 Widomski et al. Sep 2005 A1
20050251201 Roue et al. Nov 2005 A1
20050256532 Nayak et al. Nov 2005 A1
20050267495 Ginn et al. Dec 2005 A1
20050267525 Chanduszko Dec 2005 A1
20060036284 Blaeser et al. Feb 2006 A1
20060052821 Abbott et al. Mar 2006 A1
20060069408 Kato Mar 2006 A1
Foreign Referenced Citations (48)
Number Date Country
135840 Apr 1985 EP
199694 Oct 1986 EP
0265532 May 1988 EP
0375556 Jun 1990 EP
0428812 May 1991 EP
0947165 Oct 1999 EP
1260919 Jan 1972 GB
1550676 Aug 1979 GB
2 359 024 Aug 2001 GB
WO 8500018 Jan 1985 WO
WO 8704081 Jul 1987 WO
WO 9004352 May 1990 WO
WO 9115996 Oct 1991 WO
WO 9204864 Apr 1992 WO
WO 9305705 Apr 1993 WO
WO 9315791 Aug 1993 WO
WO 9400178 Jan 1994 WO
WO 9807375 Feb 1998 WO
WO 9918862 Apr 1999 WO
WO 9918864 Apr 1999 WO
WO 9918870 Apr 1999 WO
WO 9918871 Apr 1999 WO
WO 9923959 May 1999 WO
WO 9949788 Oct 1999 WO
WO 0007506 Feb 2000 WO
WO 0009027 Feb 2000 WO
WO 0113810 Mar 2001 WO
WO 0178596 Oct 2001 WO
WO 0178596 Oct 2001 WO
WO 0182778 Nov 2001 WO
WO 03022159 Mar 2003 WO
WO 03022160 Mar 2003 WO
WO 03026496 Apr 2003 WO
WO 03053493 Jul 2003 WO
WO 03071957 Sep 2003 WO
WO 03082076 Oct 2003 WO
WO 03094742 Nov 2003 WO
WO 2004019791 Mar 2004 WO
WO 2004043266 May 2004 WO
WO 2004069055 Aug 2004 WO
WO 2004082532 Sep 2004 WO
WO 2004091411 Oct 2004 WO
WO 2005006990 Jan 2005 WO
WO 2005027753 Mar 2005 WO
WO 2005034738 Apr 2005 WO
WO 2005074814 Aug 2005 WO
WO 2005046487 Dec 2005 WO
WO 2005115256 Dec 2005 WO
Related Publications (1)
Number Date Country
20050228283 A1 Oct 2005 US
Provisional Applications (1)
Number Date Country
60477532 Jun 2003 US